Diacylglycerol kinases (DGKs) inhibit diacylglycerol (DAG) signaling by phosphorylating DAG. DGK-1, the C. elegans ortholog of human neuronal DGKtheta;, inhibits neurotransmission and thus controls behavior. DGK-1, like DGKtheta;, has three cysteine-rich domains (CRDs), a pleckstrin homology (PH) domain, and a kinase domain. To identify DGK domains and amino acid residues critical for terminating DAG signaling in vivo, we analyzed 20
dgk-1 mutants defective in DGK-1 controlled behaviors. We found by sequencing that the mutations included nine amino acid substitutions and seven premature stop codons that impair the physiological functions of DGK-1. All nine amino acid substitutions are either in the second CRD, the third CRD, or in the kinase domain. Thus, these domains are important for the termination of DAG signaling by DGK-1 in vivo. Seven of the substituted amino acid residues are present in all human DGKs and likely define key residues required for the function of all DGKs. An ATP-binding site mutation expected to inactivate the kinase domain retained very little physiological function, but we found two stop codon mutants predicted to truncate DGK-1 before its kinase domain that retained significantly more function. We detected novel splice forms of
dgk-1 that can reconcile this apparent conflict, as they skip exons containing the stop codons to produce DGK-1 isoforms that contain the kinase domain. Two of these isoforms lack an intact PH domain yet appear to have significant function. Additional novel isoform(s) account for all the DGK-1 function necessary for one behavior, dopamine response.